A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study

Study Summary

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

Interventions

Study Locations

Facility	City	State	Country
Tianjin Medical University Cancer Institute & Hospital	Tianjin	Tianjin Municipality	China

Official Trial Information

View on ClinicalTrials.gov